Anderly C Chueh is an expert in Oncology at Monash University (Australia). Anderly C Chueh has authored 42 publications, the most recent in 2025. SLR score: 110 (community average: 125). How the SLR is computed.

LeadR Profile

Profile validated by the expert
Anderly C Chueh Monash University Australia
110 ScienceLeadR Reputation 110
Network Map

Oncology

Subspecialties:

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2004 - 2025
Source: PubMed

Monash University - Research Fellow

2019 - 2025

Colorado Cancer Research Program

2025 - 2025

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 42

Citations

Citations: 1 341 1st author: 9 Last author: 1 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Activation of CAMK2 by pseudokinase PEAK1 represents a targetable pathway in triple negative breast cancer.
PMID 39984440 — cells, triple negative breast neoplasms, breast neoplasms, biological science disciplines, neoplasms, calcium-calmodulin-dependent protein kinases, breast, therapeutics
Nat Commun20250
Integrative Modeling of Signaling Network Dynamics Identifies Cell Type-Selective Therapeutic Strategies for FGFR4-Driven Cancers.
PMID 39088700 — cells, triple negative breast neoplasms, carcinoma, hepatocellular, breast neoplasms, neoplasms, cell line, breast, therapeutics
Cancer Res20242
Feed-forward stimulation of CAMK2 by the oncogenic pseudokinase PEAK1 generates a therapeutically "actionable" signalling axis in triple negative breast cancer.
PMID 38405732 — triple negative breast neoplasms, cells, therapeutics, calcium-calmodulin-dependent protein kinases
bioRxiv20241
Pediatric glioma histone H3.3 K27M/G34R mutations drive abnormalities in PML nuclear bodies.
PMID 38066546 — glioma, leukemia, point mutation, histones, mutation
Genome Biol202313
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
PMID 37557181 — cell cycle, cells, therapeutics, breast neoplasms, histone acetyltransferases, histones
Cell Chem Biol202332

LeadR Networks

Main global connection map